Hydrochlorothiazide

Verify with FDA CVM →

27 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
4
Deaths Reported
1480.0%
Death Rate

Active Ingredients

Hydrochlorothiazide

Administration Routes

OralUnknown

Species Affected

Human 19
Dog 8

Most Affected Breeds

Unknown 19
Maltese 1
Terrier - Fox Wire 1
Terrier - Jack Russell 1
Retriever - Labrador 1
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Chihuahua 1
Terrier (unspecified) 1
Dog (unknown) 1

Most Reported Reactions

Accidental exposure 10
Other abnormal test result NOS 7
Hyperglycaemia 4
Elevated serum alkaline phosphatase (SAP) 3
Weakness 3
Weight loss 3
Vomiting 3
Glucosuria 3
Intentional misuse 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Injection site swelling 2
Death by euthanasia 2

Outcome Breakdown

Outcome Unknown
9 (33.3%)
Recovered/Normal
8 (29.6%)
Ongoing
4 (14.8%)
Recovered with Sequela
2 (7.4%)
Euthanized
2 (7.4%)
Died
2 (7.4%)

Data Summary

Metric Value
Total adverse event reports 27
Reports involving death 4
Case-fatality rate (reported events) 1480.0%
Distinct species in reports 2
Distinct breeds in reports 9
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Hydrochlorothiazide Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 27 adverse event reports referencing Hydrochlorothiazide, including 4 reports in which the animal died — a 1480.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Hydrochlorothiazide. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Hydrochlorothiazide reports are Human (19 reports), Dog (8 reports), with Human accounting for the largest share. Within those species, Unknown (19), Maltese (1), Terrier - Fox Wire (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Hydrochlorothiazide are Accidental exposure (10), Other abnormal test result NOS (7), Hyperglycaemia (4), Elevated serum alkaline phosphatase (SAP) (3). Of the 27 reports with a coded outcome, Outcome Unknown is the leading category at 33.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Hydrochlorothiazide.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial